Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension

Drugs
Sheridan M Hoy

Abstract

Latanoprostene bunod ophthalmic solution 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta™] is a nitric oxide (NO)-donating prostaglandin F2α analogue approved in the USA for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. It is thought to lower IOP by increasing aqueous humour outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aqueous humour outflow through the trabecular meshwork pathway (mediated by NO). Results from two multinational, phase III studies (APOLLO and LUNAR) and a pooled analysis of these studies demonstrated the noninferiority of latanoprostene bunod 0.024% to timolol ophthalmic solution 0.5% (hereafter referred to as timolol 0.5%) in terms of IOP-lowering efficacy over 3 months in patients with OAG or ocular hypertension, with the superiority of latanoprostene bunod 0.024% over timolol 0.5% subsequently demonstrated in APOLLO and the pooled analysis. Moreover, there was no apparent loss of IOP-lowering effect in subsequent safety extension periods of up to 9 months. The IOP-lowering efficacy seen in APOLLO and LUNAR was confirmed in a phase III study (JUPITER) in Japanese pat...Continue Reading

References

Aug 16, 2014·Investigative Ophthalmology & Visual Science·Megan E CavetElena Bastia
Oct 31, 2014·Journal of Ocular Biology·Diala W Abu-HassanMary J Kelley
Jun 27, 2015·Investigative Ophthalmology & Visual Science·Megan E CavetMary E Richardson
Nov 20, 2015·Ophthalmology·Bruce E PrumRuth D Williams
Jul 28, 2016·American Journal of Ophthalmology·John H K LiuRobert N Weinreb
Aug 8, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Megan E Cavet, Heleen H DeCory

❮ Previous
Next ❯

Citations

Jul 10, 2019·Journal of Glaucoma·Sunu MathewBrent Siesky
Jul 17, 2020·Chemical Record : an Official Publication of the Chemical Society of Japan ... [et Al.]·Steven H BennettVarinder K Aggarwal
Sep 20, 2018·Expert Opinion on Investigational Drugs·Artemis Matsou, Eleftherios Anastasopoulos
Feb 23, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Anas NajjarRafik Karaman
Jul 28, 2020·Expert Opinion on Pharmacotherapy·Wesam Shamseldin ShalabyL Jay Katz
Dec 14, 2018·Pharmaceutical Research·Christopher M AdamsGanesh Prasanna
Oct 7, 2020·Seminars in Ophthalmology·Ying Jiang, Courtney Ondeck
Feb 23, 2021·Journal of Medicinal Chemistry·Priyadeep BhutaniRaj Kumar
Mar 4, 2021·European Journal of Ophthalmology·Amy A MehtaDeepak P Edward
May 13, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Kuan-Ju ChenDavid Cipolla
May 21, 2021·Translational Vision Science & Technology·Wenyan WangWei Zhu
Jul 16, 2021·Therapeutic Advances in Ophthalmology·Rashmi KumariAkanchha Kumari
Apr 3, 2019·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Jun 27, 2021·Journal of Glaucoma·Jake E RadellJanet B Serle
Jan 18, 2022·Clinical & Experimental Ophthalmology·Robert J Casson

❮ Previous
Next ❯

Software Mentioned

CONSTELLATION
JUPITER
VOYAGER
LUNAR
APOLLO

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

© 2022 Meta ULC. All rights reserved